CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene editing space thanks to its pipeline potential. The Swiss biotech, which markets ...